Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives

作     者：Dmitry Victorovich Garbuzenko Nikolay Olegovich Arefyev Evgeniy Leonidovich Kazachkov 

作者机构：Department of Faculty Surgery South Ural State Medical University Department of Pathological Anatomy and Forensic MedicineSouth Ural State Medical University 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2018年第24卷第33期

页      面：3738-3748页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by RFBR according to the research project No.18-315-00434 

主　　题：Liver cirrhosis Portal hypertension Pathogenesis Angiogenesis Antiangiogenic therapy 

摘      要：Developing medicines for hemodynamic disorders that are characteristic of cirrhosis of the liver is a relevant problem in modern hepatology. The increase in hepatic vascular resistance to portal blood flow and subsequent hyperdynamic circulation underlie portal hypertension(PH) and promote its progression, despite the formation of portosystemic collaterals. Angiogenesis and vascular bed restructurization play an important role in PH pathogenesis as well. In this regard, strategic directions in the therapy for PH in cirrhosis include selectively decreasing hepatic vascular resistance while preserving or increasing portal blood flow, and correcting hyperdynamic circulation and pathological angiogenesis. The aim of this review is to describe the mechanisms of angiogenesis in PH and the methods of antiangiogenic therapy. The Pub Med database, the Google Scholar retrieval system, and the reference lists from related articles were used to search for relevant publications. Articles corresponding to the aim of the review were selected for 2000-2017 using the keywords: liver cirrhosis, portal hypertension, pathogenesis, angiogenesis, and antiangiogenic therapy. Antiangiogenic therapy for PH was the inclusion criterion. In this review, we have described angiogenesis inhibitors and their mechanism of action in relation to PH. Although most of them were studie donly in animal experiments, this selective therapy for abnormally growing newly formed vessels is pathogenetically reasonable to treat PH and associated complications.